Immix Biopharma, Inc. IMMX
NASDAQ · United States · Health Technology
$10.41-0.13 (-1.28%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Immix Biopharma’s latest clinical results showed strong patient responses to its lead CAR-T candidate as the biotech firm prepares for a planned regulatory filing in 2027.
Immix Biopharma, Inc. (NASDAQ:IMMX) reported interim data from its NEXICART-2 Phase 2 clinical trial of NXC-201 in patients with relapsed or refractory AL amyloidosis.
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Compan
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.